Get the Stockscreener App
337.60
1.19%
-4.06
After Hours:
336.60
-1.00
-0.30%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $337.60, with a volume of 8.22M.
It is down -1.19% in the last 24 hours and up +4.07% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$341.66
Open:
$344.38
24h Volume:
8.22M
Relative Volume:
2.94
Market Cap:
$182.21B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
23.48
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-4.65%
1M Performance:
+4.07%
6M Performance:
+4.06%
1Y Performance:
+16.56%
1-Day Range:
$334.05
$345.00
1-Week Range:
$334.05
$358.30
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
337.60 | 182.21B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Why Amgen’s Repatha is quietly reshaping cholesterol therapy - AD HOC NEWS
Amgen Growth Drivers Surge 24 Percent as New Core Takes Over - HarianBasis.co
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen StockGoldman Sachs trims target after obesity pipeline update - AD HOC NEWS
Amgen Rhode Island - Providence Business News
Amgen Gives Greater Los Angeles Community an Experience to Remember at FIFA Fan Festival - Amgen
What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? - Yahoo Finance
What If Amgen Stock’s Patent Worries Are Hiding Its Real Growth Engine? - Trefis
Medtronic Ruling Supports IRS In Amgen Case, Tax Court Told - Law360
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says - Moomoo
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $370 - Moomoo
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen Stock’s Gross Margin Story in Q1 2026: What the Numbers Say About a $468 Target - TIKR.com
Amgen Ends Lobbying Relationship With DC Firm - Legis1
How Patent Setback and Drug Wins Will Impact Amgen (AMGN) Investors - simplywall.st
Competitive tension builds around Amgen's Tepezza after a fresh patent ruling - AD HOC NEWS
Amgen Hires Lobbying Counsel on Drug Pricing - Legis1
New phase 3 data put Amgen’s Repatha back in the lipid spotlight - AD HOC NEWS
Amgen Inc. Stock (US0311621009): Jury patent verdict and valuation debate put shares in focus - AD HOC NEWS
Amgen Owes $20 Million in Antibody-Production Tech Patent Trial - Bloomberg Law News
Harbour BioMed Wins $20 Million Patent Verdict Against Amgen - Contract Pharma
AMGN DCF Analysis: Intrinsic Value $292 vs Price $355 - GuruFocus
The litigation lasted five years, and Amgen was found to have willfully infringed. Harbour BioMed stated, 'The favorable ruling is expected to enhance our BD negotiation leverage.' | Quick Read Announcement - 富途牛牛
Amgen Inc. (AMGN) Stock Report: Valuation Insights Amid Robust Dividend Yield and Revenue Growth - DirectorsTalk Interviews
Internal documents reveal: Denmark sues Amgen for millions following MFN exit - medwatch.com
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PR Newswire
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen’s Repatha Data Highlights at ADA 2026 Amid Analyst Price Target AdjustmentEarnings Call Highlights - newsline.com
Amgen Repatha Data Highlights Potential in Longevity Sector Following ADA PresentationRevenue Miss Report - newsline.com
Amgen's Repatha Data Bolsters Longevity Profile Amid Analyst Price Target AdjustmentLow Estimate Range - newsline.com
Amgen Shows Repatha Risk Reduction in High-Risk Diabetes Patients; Goldman Sachs Adjusts Price TargetProfit Warning Alert - newsline.com
Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Cuts Cardiovascular Risk in High Risk Diabetes Patients - HarianBasis.co
Atlas Capital Advisors Inc. Takes $2.20 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st
Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna - Insider Monkey
Wall Street Zen Upgrades Amgen (NASDAQ:AMGN) to Buy - MarketBeat
Amgen Inc. Stock (US0311621009): Biotech heavyweight in focus as investors weigh valuation and pipel - AD HOC NEWS
Victory Capital Management Inc. Grows Holdings in Amgen Inc. $AMGN - MarketBeat
State Street Corp Has $10.01 Billion Stock Position in Amgen Inc. $AMGN - MarketBeat
Van ECK Associates Corp Lowers Position in Amgen Inc. $AMGN - MarketBeat
Is Amgen Still Reasonable After Its Strong Run? - Kalkine Media
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now - Insider Monkey
Korea Investment CORP Trims Stake in Amgen Inc. $AMGN - MarketBeat
Operating expenses (excl. COGS) of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Rhenman & Partners Asset Management AB Acquires Shares of 36,000 Amgen Inc. $AMGN - MarketBeat
First National Bank of Omaha Boosts Position in Amgen Inc. $AMGN - MarketBeat
Amgen taps research firm to reassess Tavneos data - Reuters
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):